A retrospective study analysed 245 patients who received ≥1 treatment for metastatic castration-resistant disease subsequent to participating in the GETUG-AFU 15 trial. In those who had previously received androgen deprivation therapy (ADT) alone or plus docetaxel for castration-responsive disease, subsequent docetaxel (first-line or second-line) resulted in PSA decline >50% (PSA50) in 45% or 14% of men and bicalutamide resulted in PSA50 in 43% or 17% of men, respectively. Abiraterone or enzalutamide treatment in those who had received ADT plus docetaxel resulted in PSA50 in 53% of men.
References
Wallace, E. et al. Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naïve prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2017.09.022 (2017)
Rights and permissions
About this article
Cite this article
Thoma, C. Treatment after ADT plus docetaxel. Nat Rev Urol 14, 700 (2017). https://doi.org/10.1038/nrurol.2017.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.196
